文献速递免疫规划传染病防控与疫情报告

荷兰2017-2019年4CMenB疫苗对侵袭性脑膜炎球菌病的预测覆盖率

Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
PubMed 文献 · Vaccine · 2020-10-21

本研究对荷兰2017-2019年396例侵袭性脑膜炎球菌病分离株进行全基因组测序,用gMATS预测4CMenB疫苗覆盖率。B群占39%,其中73%(95%CI:64-80%)估计被覆盖,0-4岁B群覆盖率为58%(95%CI:43-72%),覆盖率随克隆复合体和年龄变化。

要点

  • 荷兰侵袭性脑膜炎球菌病以W群(45%)和B群(39%)为主,0-4岁发病率最高(4例/10万)。
  • B群分离株中73%(95%CI:64-80%)估计被4CMenB覆盖,0-4岁B群覆盖率58%(95%CI:43-72%)。
  • 4CMenB覆盖率因克隆复合体和年龄而异,需持续监测流行株并确定合适接种年龄组。

核心结论

  • 4CMenB疫苗对荷兰B群侵袭性脑膜炎球菌病的预测覆盖率为73%(95%CI:64-80%),覆盖率随克隆复合体和年龄变化。

研究设计与样本

  • 对荷兰参考实验室2017-2019两个流行病学年度收到的全部侵袭性脑膜炎球菌分离株进行全基因组测序,共396例,用gMATS预测4CMenB覆盖率。

主要发现

  • 396例侵袭性脑膜炎球菌病发病率为1.22例/10万居民,其中W群180例(45%)、B群155例(39%)、Y群46例(12%)、C群10例(3%)。
  • 0-4岁发病率最高(4例/10万居民),该年龄组57/72例(79%)为B群;45岁及以上以W群为主(110/187例,59%)。
  • B群分离株包含11个克隆复合体,103/122株(84%)属于cc32、cc41/44、cc269和cc213四个克隆复合体;W群95%属于cc11。
  • 122株B群分离株中89株(73%;95%CI:64-80%)估计被4CMenB覆盖,0-4岁43株B群中25株(58%;95%CI:43-72%)估计被覆盖。

临床怎么用

  • 4CMenB疫苗覆盖率依赖于循环克隆复合体,应持续监测脑膜炎球菌流行株。
  • 估计年龄特异性覆盖率有助于确定疫苗接种的目标年龄组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/105 inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/105 inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to cc11. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Freudenburg-de Graaf W, Knol MJ, van der Ende A, et al. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands. Vaccine. 2020. PMID: 33097311. doi:10.1016/j.vaccine.2020.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。